Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | DHFR | P00374 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.42 |
| ▸ | METAP2 | P50579 | 1/20 | 0.41 |
| ▸ | METAP1 | P53582 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14869399 | 0.89 | SMN1; SMN2 (0.58) | SMN1; SMN2RAB9ADHFRMAPTLMNA | |
| SCHEMBL14869432 | 0.83 | SMN1; SMN2 (0.52) | SMN1; SMN2RAB9ADHFRMAPTLMNA | |
| SCHEMBL8507343 | 0.82 | AOC3 (0.47) | SMN1; SMN2RAB9ADHFRAOC3 | |
| SCHEMBL14869415 | 0.79 | SMN1; SMN2 (0.49) | SMN1; SMN2RAB9ADHFRMAPTLMNA | |
| SCHEMBL32688111 | 0.79 | SMN1; SMN2 (0.43) | SMN1; SMN2RAB9AMAPTLMNAALDH1A1 | |
| SCHEMBL795407 | 0.78 | MAPT (0.58) | SMN1; SMN2RAB9ADHFRMAPTLMNA | |
| SCHEMBL8413870 | 0.77 | HTR2B (0.57) | SMN1; SMN2RAB9ADHFRLMNA | |
| SCHEMBL795537 | 0.76 | ALDH1A1 (0.50) | SMN1; SMN2RAB9ADHFRMAPTLMNA | |
| SCHEMBL17220070 | 0.75 | SMN1; SMN2 (0.45) | SMN1; SMN2RAB9ADHFRMAPTLMNA | |
| SCHEMBL9751562 | 0.74 | PDE4A (0.43) | SMN1; SMN2RAB9AMAPTALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2616465-B1 | TRIAZINE-OXADIAZOLES | NOVARTIS AG (CH) | 2015-11-04 | — | — | EP | disclosed |
| US-20150025057-A1 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2015-01-22 | — | — | US | disclosed |
| US-8895733-B2 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2014-11-25 | — | — | US | disclosed |
| US-20140051676-A1 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2014-02-20 | — | — | US | disclosed |
| EP-2616465-A1 | TRIAZINE-OXADIAZOLES | Novartis AG (CH) | 2013-07-24 | — | — | EP | disclosed |
| WO-2012035023-A1 | TRIAZINE-OXADIAZOLES | NOVARTIS AG (CH) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025057-A1 | Triazine-oxadiazoles | OPRK1, OPRD1, OPRL1 | SMN1; SMN2 1684/4885RAB9A 4766/4885DHFR 1553/4885 |
| US-20140051676-A1 | Triazine-oxadiazoles | OPRK1, OPRD1, OPRL1 | SMN1; SMN2 1684/4885RAB9A 4766/4885DHFR 1553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.